PT  - JOURNAL ARTICLE
AU  - Kaku, Chengzi I.
AU  - Champney, Elizabeth R.
AU  - Normark, Johan
AU  - Johnson, Carl E.
AU  - Ahlm, Clas
AU  - Sakharkar, Mrunal
AU  - Ackerman, Margaret E.
AU  - Forsell, Mattias N. E.
AU  - Walker, Laura M.
TI  - Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination
AID  - 10.1101/2021.12.13.21267598
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.13.21267598
4099  - http://medrxiv.org/content/early/2021/12/14/2021.12.13.21267598.short
4100  - http://medrxiv.org/content/early/2021/12/14/2021.12.13.21267598.full
AB  - Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy and address ongoing vaccine supply challenges. Here, we longitudinally profiled SARS-CoV-2 spike (S)-specific serological and memory B cell (MBC) responses in individuals receiving either homologous (ChAdOx1:ChAdOx1) or heterologous (ChAdOx1:mRNA-1273) prime-boost vaccination. Heterologous mRNA booster immunization induced significantly higher serum neutralizing antibody and MBC responses compared to homologous ChAdOx1 boosting. Specificity mapping of circulating S-specific B cells revealed that mRNA-1273 booster immunization dramatically immunofocused ChAdOx1-primed responses onto epitopes expressed on prefusion-stabilized S. Monoclonal antibodies isolated from mRNA-1273-boosted participants displayed higher binding affinities and increased breadth of reactivity against variants of concern (VOCs) relative to those isolated from ChAdOx1-boosted participants. Overall, the results provide fundamental insights into the B cell response induced by ChAdOx1 and a molecular basis for the enhanced immunogenicity observed following heterologous mRNA booster vaccination.Competing Interest StatementC.I.K., E.R.C., C.E.J., M.S., and L.M.W. are employees of Adimab, LLC, and may hold shares in Adimab, LLC. L.M.W. is an employee of Adagio Therapeutics, Inc., and holds shares in Adagio Therapeutics, Inc. J.N., C.A., and M.N.E.F. declare no competing interests.Clinical TrialEUDRACT Number 2021-000683-30Funding StatementM.N.E.F is funded by grants from the Swedish Research Council (2020-06235) and from the SciLifeLab National COVID-19 Research Program (VC-2020-0015), financed by the Knut and Alice Wallenberg Foundation. C.A. is funded by the Swedish Research Council (2021-04665). J.N. is a Wallenberg Center for Molecular Medicine Associated Researcher.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The clinical trial, CoVacc - Immune response to vaccination against Covid-19, an open multicenter phase IV study, was approved by the Swedish Ethics Review Authority (Dnr 2021- 00055) and the Medical Products Agency Sweden.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAntibody sequences have been deposited in GenBank (#OL697893-OL698712). All other data are available in the manuscript or supplementary materials. IgGs are available from L.M.W. under a material transfer agreement (MTA) from Adagio Therapeutics, Inc.